Processa Pharmaceuticals (PCSA) Accumulated Expenses (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Accumulated Expenses came in at $1.1 million in Q1 2026, up 67.42% YoY from $680747.0 in Q1 2025, and down 3.37% on a QoQ basis from $1.2 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Accumulated Expenses (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Accumulated Expenses data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Accumulated Expenses rose 67.42% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 67.42% YoY) and the FY2025 annual result came in at $1.2 million, up 103.8% from the prior year.
- Accumulated Expenses declined to $1.1 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.6 million in Q1 2023 to a low of $146274.0 in Q4 2023.
- A 5-year average of $629585.5 and a median of $465618.0 in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 22199.24% — and 2024, when it tumbled 70.42%.
- Tracing PCSA's Accumulated Expenses over 5 years: stood at $403061.0 in 2022, then plunged by 63.71% to $146274.0 in 2023, then surged by 295.65% to $578731.0 in 2024, then jumped by 103.8% to $1.2 million in 2025, then decreased by 3.37% to $1.1 million in 2026.
- The last three Accumulated Expenses figures came in at $1.1 million (Q1 2026), $1.2 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.14 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 680,747.00 |
| Dec 31, 2024 | 578,731.00 |
| Sep 30, 2024 | 412,813.00 |
| Jun 30, 2024 | 505,397.00 |
| Mar 31, 2024 | 465,618.00 |
| Dec 31, 2023 | 146,274.00 |
| Sep 30, 2023 | 202,236.00 |
| Jun 30, 2023 | 311,502.00 |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | 403,061.00 |
| Sep 30, 2022 | 216,407.00 |
| Jun 30, 2022 | 307,412.00 |
| Mar 31, 2022 | 292,566.00 |
| Dec 31, 2021 | 279,265.00 |
| Sep 30, 2021 | 378,660.00 |
| Jun 30, 2021 | 369,110.00 |